Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
cancer
8
×
detroit blog main
detroit top stories
indiana blog main
indiana top stories
life sciences
medicare
8
×
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
8
×
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
clinical trials
eli lilly
pfizer
biogen
bristol-myers squibb
cancer immunotherapy
deals
merck
nivolumab
novartis
startups
What
bio
roundup
drug
companies
plan
price
alzheimer’s
drugs
gene
life
new
patients
pharmaceutical
prices
science
talk
week
year
advantages
annual
answer
appetite
approval
arena’s
assessed
attention
away
bar
becker
billions
biogen’s
biopharmaceutical
biotech
black
bounty
bread
brings
butter
buyout
cancer
Language
unset
Current search:
medicare
×
cancer
×
" raleigh-durham blog main "
×
@xconomy.com
4 years ago
Pelosi, Dems Unveil Price Plan: Are 25 Drugs Enough for Negotiation?
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com
5 years ago
Bio Roundup: Moderna’s IPO, Arena’s Comeback, E-Cig Survey & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More